The role of Fc receptors in HIV prevention and therapy.

Over the past decade, a wealth of experimental evidence has accumulated supporting the importance of Fc receptor (FcR) ligation in antibody-mediated pathology and protection in many disease states. Here we present the diverse evidence base that has accumulated as to the importance of antibody effector functions in the setting of HIV prevention and therapy, including clinical correlates, genetic associations, viral evasion strategies, and a rapidly growing number of compelling animal model experiments. Collectively, this work identifies antibody interactions with FcR as important to both therapeutic and prophylactic strategies involving both passive and active immunity. These findings mirror those in other fields as investigators continue to work toward identifying the right antibodies and the right effectors to be present at the right sites at the right time.

Nomenclature of Toso, Fas apoptosis inhibitory molecule 3, and IgM FcR.

Hiromi Kubagawa and John E. Coligan coordinated an online meeting to define an appropriate nomenclature for the cell surface glycoprotein presently designated by different names: Toso, Fas apoptosis inhibitory molecule 3 (FAIM3), and IgM FcR (FcµR). FAIM3 and Faim3 are the currently approved symbols for the human and mouse genes, respectively, in the National Center for Biotechnology Information, Ensembl, and other databases. However, recent functional results reported by several groups of investigators strongly support a recommendation for renaming FAIM3/Faim3 as FCMR/Fcmr, a name better reflecting its physiological function as the FcR for IgM. Participants included 12 investigators involved in studying Toso/FAIM3(Faim3)/FµR, representatives from the Human Genome Nomenclature Committee (Ruth Seal) and the Mouse Genome Nomenclature Committee (Monica McAndrews), and an observer from the IgM research field (Michael Carroll). In this article, we provide a brief background of the key research on the Toso/FAIM3(Faim3)/FcµR proteins, focusing on the ligand specificity and functional activity, followed by a brief summary of discussion about adopting a single name for this molecule and its gene and a resulting recommendation for genome nomenclature committees.

The Xenopus FcR family demonstrates continually high diversification of paired receptors in vertebrate evolution.

BACKGROUND: Recent studies have revealed an unexpected diversity of domain architecture among FcR-like receptors that presumably fulfill regulatory functions in the immune system. Different species of mammals, as well as chicken and catfish have been found to possess strikingly different sets of these receptors. To better understand the evolutionary history of paired receptors, we extended the study of FcR-like genes in amphibian representatives Xenopus tropicalis and Xenopus laevis. RESULTS: The diploid genome of X. tropicalis contains at least 75 genes encoding paired FcR-related receptors designated XFLs. The allotetraploid X. laevis displays many similar genes primarily expressed in lymphoid tissues. Up to 35 domain architectures generated by combinatorial joining of six Ig-domain subtypes and two subtypes of the transmembrane regions were found in XFLs. None of these variants are shared by FcR-related proteins from other studied species. Putative activating XFLs associate with the FcRgamma subunit, and their transmembrane domains are highly similar to those of activating mammalian KIR-related receptors. This argues in favor of a common origin for the FcR and the KIR families. Phylogenetic analysis shows that the entire repertoires of the Xenopus and mammalian FcR-related proteins have emerged after the amphibian-amniotes split. CONCLUSION: FcR- and KIR-related receptors evolved through continual species-specific diversification, most likely by extensive domain shuffling and birth-and-death processes. This mode of evolution raises the possibility that the ancestral function of these paired receptors was a direct interaction with pathogens and that many physiological functions found in the mammalian receptors were secondary acquisitions or specializations.

Episodes of natural selection shaped the interactions of IgA-Fc with FcalphaRI and bacterial decoy proteins.

FcalphaRI, a receptor for IgA-Fc, recruits myeloid cells to attack IgA-coated pathogens. By competing with FcalphaRI for IgA, bacterial decoys, like SSL7 of Staphylococcus aureus, subvert this defense. We examined how pathogen selection has driven the diversification and coevolution of IgA and FcalphaRI. In higher primates, the IgA binding site of FcalphaRI diversified under positive selection, a strong episode occurring in hominoid ancestors about the time of the IgA gene duplication. The differential binding of SSL7 to IgA-Fc of different species correlates with substitution at seven positions in IgA-Fc, two of which were positively selected in higher primates. Two others, which reduce SSL7 binding, emerged during episodes of positive selection in the rabbit and rodent lineages. The FcalphaRI-IgA interaction evolves episodically under two types of positive selection: pressure from pathogen decoys selects for IgA escape variants which, in turn, selects for FcalphaRI variants to keep up with the novel IgA. When FcalphaRI cannot keep up, its function is lost and the gene becomes susceptible to elimination, as occurred in the mouse genome, either by chance or selection on one of the many linked, variable immune system genes. A cluster of positively selected residues presents a putative binding site for unknown IgA-binding factors.

The first avian Ig-like Fc receptor family member combines features of mammalian FcR and FCRL.

Homologues of almost all mammalian Ig-like immunoregulatory receptor families have been found in the chicken, except the Fc receptor (FcR) family. In addition to classical FcRs that specifically bind antibodies and mediate their effector functions, this family includes "Fc receptor-like" (FCRL) proteins for which ligands have yet to be identified. We have cloned and expressed a full-length chicken monocyte transcript that encodes an avian homologue of the mammalian FcR family. We have termed it chFcR/L as it possesses characteristics of both mammalian FcR and FCRL, but is phylogenetically distinct from either. chFcR/L is a transmembrane protein with four extracellular Ig-like domains and a short cytoplasmic tail. It can be expressed on the cell surface only in the presence of an accessory molecule, chFcRgamma, through which it acquires signalling potential.

Severity of Guillain-Barré syndrome is associated with Fc gamma Receptor III polymorphisms.

Macrophages and ganglioside-specific IgG are involved in the pathogenesis of Guillain-Barre syndrome (GBS). Leukocyte IgG receptors (Fc gammaR) confer potent cellular effector functions to the specificity of IgG. The efficacy of IgG-mediated cellular inflammatory responses is determined by functional polymorphisms of three Fc gammaR subclasses (Fc gammaRIIa: H131/R131; Fc gammaRIIIa: V158/F158; Fc gammaRIIIb: NA1/NA2). Fc gammaR genotype distributions were determined in a Dutch, and British cohort of GBS patients and controls. In addition, a meta-analysis incorporating all previously published data, encompassing a total of 345 GBS patients and 714 healthy controls, was performed. Results suggest that Fc gammaRIII genotypes may represent mild disease-modifying factors in GBS.

FCRL, a novel member of the leukocyte Fc receptor family possesses unique structural features.

A novel conserved member of the leukocyte Fc receptor (FcR) family was identified in human and mouse. The presumably secreted protein, designated FCRL (FcR-like) is comprised of four domains. The three N-terminal domains are related to the extracellular region of FcgammaRI, with the second (35-37% residue identity) and the third (46-52%) domains showing highest similarity. The C-terminal domain is a unique sequence enriched with proline residues. In humans, alternative transcripts for six FCRL isoforms were revealed. Spleen and tonsils were found to be the major sources of FCRL mRNA in human tissues. Western blotting of tonsil cell lysate using FCRL-specific antibodies recognized a 44-kDa protein produced as a monomer containing free sulfhydryl groups. The monomer, however, was able to form disulfide-linked homo-oligomer upon oxidation. In COS-7 cells transiently transfected with two human FCRL isoforms, both resided intracellularly. Immunohistochemical staining of tonsil sections demonstrated the FCRL expression in germinal centers, suggesting that the protein may be implicated in germinal center-specific stages of B cell development. The phylogenetic analysis of the FCRL relationships with the leukocyte FcR supports a view that the three-domain structure was primordial in the evolution of the family.

Building up the family of ITIM-bearing negative coreceptors.

The acronym (ITAM) for immunoreceptor tyrosine-based activation motif was first proposed in September 1994, during the 8th Meeting on Signals and Signal Processing in the Immune System held in Kecskemet, Hungary, to designate the di-tyrosine-based YxxL activation motifs that had been previously understood by Michael Reth to account for the cell-triggering properties of BCR, TCR and FcR. It was then agreed, by those who signed the collective letter John Cambier had been commissioned to submit to Immunology Today (Cambier, J.C. (1994) Immunol. Today 16, 110-110) that it was premature to propose ITIM (for immunoreceptor tyrosine-based inhibition motif) to designate the one inhibitory sequence containing a single Ys1L motif that had been identified in the intracytoplasmic domain of a low-affinity Fc receptor for IgG. Right away, ITAM became unanimously accepted and widely used in the literature. Remarkably, ITIM was soon adopted too and, in September 1996, a whole session of the 9th Signal Meeting, held in Tihany, Hungary, was devoted to ITIM. During the last 2 years, evidence accumulated that indeed accredited the ITIM concept.

Receptores Fc. Distribución, estructura y función

Muchas de las funciones esenciales del sistema inmune son mediadas por glicoproteínas de superficie conocidas como receptores Fc (FcR), que interaccionan en forma específica con el dominio constante o región Fc de inmunoglobulinas homólogas. Se encuentran ampliamente distribuidos entre las células del sistema inmune y tienen especificidad por diferentes isotipos de inmunoglobulinas. Las cadenas proteicas que componen los FcR contienen una región extracelular, una región transmembranal y una región intracelular. La región extracelular es altamente conservada mientras que la citoplasmática es muy heterogénea, lo que parece explicar las diferencias funcionales existentes entre los FcR expresados por las distintas células. El análisis molecular de genes y proteínas que constituyen los FcR ha mostrado una diversidad de estructuras, subunidades proteicas y vías para la transducción de señales que son compartidas con otros receptores del sistema inmune. Conocer las funciones específicas para cada uno de los FcR y el mecanismo a través del cual ocurre la transducción de señales para la activación celular permitirá un mejor entendimiento del papel inmunorregulador de los FcR y su utilización en el diseño de alternativas terapéuticas para varios desórdenes inmunológicos en los cuales participan.

[Fc gamma receptors: structure, function, and clinical significance]. / Fc gamma-Rezeptoren: Struktur, Funktion und klinische Bedeutung.

Fc gamma receptors are a group of three different receptors with several subtypes. They are widely distributed on many cells of the immune system and contribute to the pathogenesis of immune complex- and autoantibody-mediated diseases such as vasculitis, rheumatoid arthritis, idiopathic thrombocytopenic purpura or autoimmune neutropenia. This review focuses on the structure, distribution and function in Fc gamma receptors and their subtypes.

Changes in IgG Fc receptor expression induced by phorbol 12-myristate 13-acetate treatment of THP-1 monocytic leukemia cells.

We studied changes in the three types of Fc gamma receptor (FcR) on the THP-1 human monocytic leukemia cells, after incubation with the phorbol ester, PMA, which has been shown to alter the expression of several genes in these cells. THP-1 cells constitutively express FcRI and FcRII, and PMA down-regulated the expression of both FcRI and FcRII. The FcRIII expression was not detected on either untreated or PMA-treated cells. Addition of PMA to THP-1 cells also resulted in a dose-dependent decrease of CD4 expression, as well as in an increased expression of activation-associated antigens. PMA treatment was followed by a progressive decrease in the steady state level of FcRI mRNA, while FcRII mRNA levels did not change, pointing to different regulatory mechanisms at the pre- and post-transcriptional level respectively. The FcRIII mRNA was undetectable. In order to further delineate the mechanism by which PMA induces alterations in FcR expression, we treated cells with stimulators of protein kinase C, of Ca2+ calmodulin-dependent kinase, and of protein kinase A. Since stimulation of none of these second messenger systems induced similar alterations in FcR expression as PMA we next tested the effects of PMA on differentiation and arrest of proliferation. The changes in FcR only occurred at PMA concentrations capable of inducing cell adherence and an arrest of proliferation, and showed a relatively slow time pattern. This suggested that the alterations in FcR expression may be linked to partial differentiation into a more macrophage-like cell. The changes in FcR expression could furthermore be reproduced by 1,25(OH)2 vitamin D3, another agent capable of differenting monocytes. In conclusion, PMA treatment of THP-1 cells decreases FcRI gene transcription and membrane expression and reduces membrane expression of FcRII. Both changes might be linked with an arrest of cell growth and induction of differentiation.

Different abilities of two types of Fc gamma receptor on guinea-pig macrophages to trigger the phosphatidylinositol turnover.

When exposed to hen ovalbumin (OA) complexes of IgG antibodies, guinea-pig macrophages were found to augment the phosphatidylinositol (PI) turnover. This response depended on the IgG isotype of antibodies used; OA complex of IgG2 antibody (OA gamma 2) triggered it about 3 times more effectively than did OA complex of IgG1 antibody (OA gamma 1). The inhibition experiments with monoclonal antibodies to Fc gamma 1/gamma 2R and Fc gamma 2R showed that Fc gamma 2R triggered activation of the PI turnover more intensively than did Fc gamma 1/gamma 2R. The same results were also obtained by the cross-linking of Fc gamma 2Rs or Fc gamma 1/gamma 2Rs by a combination of anti-mouse IgG F(ab')2 and anti-Fc gamma 2R F(ab')2 or anti-Fc gamma 1/gamma 2R F(ab')2. As the number of Fc gamma 2R molecules per macrophage is about one-half that of Fc gamma 1/gamma 2R molecules, the ability of Fc gamma 2R to trigger the response was found to be much greater than that of Fc gamma 1/gamma 2R. Despite this difference, neither the activity of Fc gamma 2R nor that of Fc gamma 1/gamma 2R to augment the PI turnover were affected by depletion of the intracellular Ca2+ by incubating the cells with Ionomycin and EGTA, and also by the treatment with pertussis toxin.

Regulation of Fc gamma receptor subtype expression on a human eosinophilic leukemia cell line EoL-3: participation of cAMP and protein kinase C in the effects of interferon-gamma and phorbol ester.

We investigated the effects of interferon-gamma (IFN-gamma), phorbol myristate acetate (PMA), and dibutyryl cAMP (Bt2cAMP) on Fc gamma R subtype expression on a human eosinophilic leukemia cell line, EoL-3. Unstimulated EoL-3 cells expressed Fc gamma RII as determined by monoclonal antibody (mAb) IV-3, whereas there was little or no Fc gamma RI and Fc gamma RIII expression as determined by mAbs 32.2 and 3G8, respectively. IFN-gamma induced Fc gamma RI expression, and Bt2 cAMP, which did not induce Fc gamma RI expression by itself, showed an additive effect on IFN-gamma-induced Fc gamma RI expression. Fc gamma RII expression was augmented by IFN-gamma, PMA, and Bt2 cAMP. Bt2 cAMP also showed an additive effect on IFN-gamma-augmented Fc gamma RII expression. Fc gamma RIII expression could be induced only by IFN-gamma plus Bt2 cAMP. H-7, a protein kinase C (PK-C) inhibitor, suppressed the enhancement of Fc gamma R subtype expression induced by these reagents. These results show that Fc gamma R subtype expression on EoL-3 cells is regulated differently in each subtype and that cAMP and PK-C play important roles in the regulation.

Signal transduction mechanisms through Fc gamma receptors on the mouse macrophage surface.

Mouse macrophages and macrophage cell lines such as P388D1 or J774 carry at least two distinct Fc gamma receptors (Fc gamma R): one specific for the Fc portion of IgG2a (Fc gamma aR, also classified as Fc gamma RI) and another for IgG2b (Fc gamma 2bR, also classified as Fc gamma RII beta). These Fc gamma Rs should transmit, upon binding of an appropriate ligand, a specific signal that leads to the regulation of macrophage functions, as the interaction of immune complex with cell surface receptor has been shown to lead to suppression of the humoral immune response or B cell differentiation, to the destruction of target cells by antibody-dependent cell-mediated cytotoxicity, to activation of arachidonic acid metabolic cascade, to the phagocytosis of opsonized particles, or to the generation of superoxide anion. In this review, we first describe evidence that Fc gamma 2aR and Fc gamma 2bR are associated with casein kinase II and phospholipase A2 activity, respectively. We will then discuss a potential role for these enzymatic activities in signal transduction pathways that leads to the activation of the arachidonic acid metabolic cascade and adenylate cyclase, to the regulation of phagocytosis, and to the suppression of interferon-gamma action to induce Ia antigens.

Localization of three subtypes of Fc gamma receptors in human placenta by immunohistochemical analysis.

We investigated the localization of the three subtypes of (Fc gamma R) in the normal human placenta using immunohistochemical and immunocytochemical techniques with specific monoclonal antibodies. The analysis revealed that Fc gamma RI was expressed on Hofbauer cells, that Fc gamma RII was expressed on Hofbauer cells and endothelial cells of fetal vessels, while Fc gamma RIII was expressed on trophoblasts, especially syncytiotrophoblasts. Moreover, we demonstrated that the expression of Fc gamma RI and Fc gamma RII on Hofbauer cells and endothelial cells of the fetal vessels in the 1st trimester placenta was different from that in the 3rd trimester placenta. These results, therefore, indicate that the three subtypes of Fc gamma R in the human placenta may contribute to maintenance of placental functions, because each Fc gamma R molecule displays unique biological functions similar to those on leukocytes.